Skip to main
KZR

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences is showing promising developments as the lifting of the partial clinical hold in autoimmune hepatitis (AIH) boosts investor confidence in the risk–benefit profile of its leading candidate, Zetomipzomib (KZR-616). The potential full removal of the clinical hold in lupus nephritis (LN) could significantly enhance the company’s commercial prospects and overall investment appeal. This advancement indicates a positive trajectory for Zetomipzomib, paving the way for increased clinical uptake and broader market opportunities if further approvals are secured.

Bears say

Kezar Life Sciences Inc is facing significant financial challenges, evidenced by a widening net loss reported in the latest quarter, which indicates higher operational costs that could strain cash reserves. Additionally, the company has limited revenue generation to date, primarily reliant on funding from equity offerings to support its clinical pipeline, raising concerns about long-term sustainability. Moreover, delays in clinical trial progress for its key product candidates may hinder potential milestones and negatively impact investor confidence.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.